title: Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression.
abstract: HER2 amplification and overexpression is observed in approximately 20% of breast cancers and is strongly associated with poor prognosis and therapeutic responsiveness to HER2 targeted agents. A recent study by Bose and colleagues suggests that another subset of breast cancer patients without HER2 amplification but with activating HER2 mutation might also benefit from existing HER2-targeted agents and the authors functionally characterize these somatic mutations in experimental models. In a second study on HER2-driven breast cancer, Angelini and colleagues investigate how the constitutively active, truncated carboxy-terminal fragment of HER2, p95HER2, promotes metastatic progression through non-cellautonomous secretion of factors from senescent cells. These new findings advance our understanding of HER2 biology in the context of HER2 activation as well as offer new insights into our understanding of drug sensitivity and metastatic progression.
authors: Swarnali
authors: S
authors: Acharyya
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000556:secondary*; D002450:Cell Communication; D016922:Cellular Senescence / Q000502:physiology*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D009154:Mutation / Q000235:genetics*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
references: Nature. 2012 May 16;486(7403):400-4
references: 22722201
references: Oncogene. 2009 Feb 12;28(6):803-14
references: 19060928
references: Cancer Res. 2007 May 1;67(9):4190-8
references: 17483330
references: Oncogene. 2007 Oct 4;26(45):6469-87
references: 17471238
references: Cancer Discov. 2013 Feb;3(2):224-37
references: 23220880
references: Nature. 2010 Aug 12;466(7308):869-73
references: 20668451
references: Nature. 2012 Oct 4;490(7418):61-70
references: 23000897
references: Nature. 2012 Jun 20;486(7403):405-9
references: 22722202
references: Mol Cell Biol. 2009 Jun;29(12):3319-31
references: 19364815
references: Cancer. 2005 Feb 1;103(3):442-3
references: 15578684
references: J Clin Oncol. 2002 Feb 1;20(3):719-26
references: 11821453
references: Lancet. 2012 Feb 18;379(9816):633-40
references: 22257673
references: N Engl J Med. 2001 Mar 15;344(11):783-92
references: 11248153
references: Clin Cancer Res. 2006 Jan 1;12(1):57-61
references: 16397024
references: Nature. 2009 Oct 8;461(7265):809-13
references: 19812674
references: Science. 1987 Jan 9;235(4785):177-82
references: 3798106
references: Clin Cancer Res. 2002 Feb;8(2):347-53
references: 11839648
references: Rev Endocr Metab Disord. 2007 Sep;8(3):269-77
references: 17899385
references: J Natl Cancer Inst. 2007 Apr 18;99(8):628-38
references: 17440164
references: Nat Rev Clin Oncol. 2011 Jun;8(6):344-56
references: 21487419
references: Cancer Res. 2013 Jan 1;73(1):450-8
references: 23288917
references: Sci Transl Med. 2012 Mar 28;4(127):127rv2
references: 22461643
references: Cancer Metastasis Rev. 2010 Jun;29(2):273-83
references: 20390322
references: Nature. 2012 Jun 10;486(7403):353-60
references: 22722193